期刊文献+

达格列净的合成 被引量:6

Synthesis of dapagliflozin
下载PDF
导出
摘要 以5-溴-2-氯苯甲酸为原料,经酰氯化、傅克酰化反应、还原得中间体5-溴-2-氯-4'-乙氧基二苯甲烷,该中间体与2,3,4,6-四-O-三甲基硅基-D-葡萄糖酸内酯经缩合、醚化、脱甲氧基、酯化、脱保护得目标化合物,总收率45%,纯度99.1%,其结构经1H NMR及MS确证。 Dapagliflozin was synthesized from 5-bromo-2-chlorobenzoic acid via chlorination,Friedel-Crafts acylation reaction and reduction to give 5-bromo-2-chloro-4'-ethoxyldiphenylmethane,which was condensed with 2,3,4,6-tetra-O-trimethylsilyl-D-glucono-1,5-lactone.Finally,dapagliflozin was obtained wia the removal of the methoxy,esterification and deprotection with an overall yield of 45% and a purity of 99. 1%. The target compound was characterized by1 H NMR and MS.
出处 《化学研究与应用》 CAS CSCD 北大核心 2016年第4期530-533,共4页 Chemical Research and Application
关键词 SGLT2抑制剂 达格列净 降糖药 合成 SGLT2 inhibitor dapagliflozin antidiabetic drug synthesis
  • 相关文献

参考文献9

  • 1DeFronzo R A, Davidson J A, Del Prato S. The role of the kidneys in glucose honeosasis : a new path towards normali- zing glycaemia[J]. Diabetes Obes Metab, 2012,14 ( 1 ) : 5-14. 被引量:1
  • 2Kakinuma H, Oi T, Tsuchiya Y H, et al. ( 1 S) -1,5-An- hydro-l-[ 5-( 4-ethoxybenzyl )-2-methoxy-4-methylphe-nyl ] -l-thio-D-glueitol ( TS-071 ) is a potent, selective sodi- um-dependent glucose cotransporter 2 ( SGLT2 ) inhibitor for type 2 diabetes[J]. J Med Chem,2010,53:3 247-3 261. 被引量:1
  • 3Meng W, Ellsworth B A, Nirsehl A A, et al. Discovery of dapagliflozin : a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) Inhibitor for the treatment of type 2 diabetes [J]. J Med Chem,2008,51 ( 5 ) : 1 145-1 149. 被引量:1
  • 4邵华,赵桂龙,刘巍,王玉丽,徐为人,汤立达.SGLT2抑制剂Dapagliflozin的全合成[J].合成化学,2010,18(3):389-392. 被引量:14
  • 5Song Y, Chen Y, Cheng H, et al. Preparation of benzyl-benzene glycoside derivatives as antidiabetic agents [P]. WO : 2009026537,2009 -02 -26. 被引量:1
  • 6Liou J, Wu Y, Li S, et al. Processes for the preparation of C-aryl glycoside amino acid complexes as potential sglt2 inhibitors [P]. WO :2010022313. 2010-02-25. 被引量:1
  • 7Deshpande P P, Ellsworth B A, Singh J, et al. Methods of producing C-aryl glucoside SGLT2 inhibitors [P]. US: 20040138439,2004 -07 -15. 被引量:1
  • 8黄坤,姜海龙,吴于兰,褚青松.达格列净的合成[J].中国医药工业杂志,2015,46(7):680-682. 被引量:5
  • 9禹艳坤,冀亚飞.达格列净的合成[J].中国医药工业杂志,2011,42(2):84-87. 被引量:15

二级参考文献18

  • 1埃尔斯沃斯·B,沃什伯恩·w·N,谢尔·P·M.C.芳基葡糖苷SGLT2抑制剂和方法[P].CN03811353.8,2005. 被引量:1
  • 2Francisco C, Kinne R K H, Wilhelm B. Thioglycosides as pharmaceutically active agents [ P ]. EP 1 854 806, 2007. 被引量:1
  • 3Meng W, Ellsworth B A, Nirschl A A, et al. Discovery of dapaglitlozin : A potent, selective renal sodiumdependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 ciabetes[J]. J Med Chem, 2008,51 : 1145 - 1149. 被引量:1
  • 4Bailey CJ,Gross JL,Pieters A,et al.Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin:a randomized,double-blind,placebocontrolled trial[J].Lancet,2010,375(9733):2223-2233. 被引量:1
  • 5Meng W,Ellsworth BA,Nirschl AA,et al.Discovery of dapagliflozin:a potent,selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes[J].JMedChem,2008,51 (5):1145-1149. 被引量:1
  • 6Eckhardt M,Eickelmann P,Himmelsbach F,et al.Glucopyranosyl-substituted benzonitrile derivatives,pharmaceutical compositions containing such compounds,their use and process for their manufacture:WO,2007093610[P].2007-08-23.(CA 2007,147:277850). 被引量:1
  • 7Song YL,Chen YW,Cheng HW,et al.Benzylbenzenederivatives and methods of use:WO,2009026537[P].2009-02-26.(CA 2009,150:237833). 被引量:1
  • 8Liou J,Wu YL,Li SB,et al.Processes for the preparation of SGLT2 inhibitors:WO,2010022313[P].2010-02-25.(CA 2010,152:287663). 被引量:1
  • 9Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes [J]. JMed Chem, 2008, 51 (5): 1145-1149. 被引量:1
  • 10Song YL, Chen YW, Cheng HW, et al. Benzylbenzene derivatives and methods of use: WO, 2009026537 [P]. 2009-02-26. (CA 2009, 150: 237833). 被引量:1

共引文献25

同被引文献46

引证文献6

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部